UBS AM’s Larimar Therapeutics LRMR Stock Holding History

UBS AM’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,569	Closed	-$1.22M	–	2713
2015 Q1	$1.22M	Buy	+2,569	New	+$1.22M	﹤0.01%	1556

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TRV

Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM's LRMR Position: Q2 2015 in Review

UBS AM sold out of Larimar Therapeutics (LRMR) in Q2 2015, closing a stake of 2,569 shares — an estimated $1.22M sold.

UBS AM first reported a position in LRMR in Q1 2015 and held it in 1 quarter. The position peaked at $1.22M in Q1 2015. 89 funds tracked by Wall St. Rank hold LRMR as of Q2 2015.

UBS AM reported no remaining Larimar Therapeutics position as of Q2 2015 after selling out during the quarter.
UBS AM sold 2,569 Larimar Therapeutics shares in Q2 2015, an estimated $1.22M.
UBS AM first reported a position in Larimar Therapeutics in Q1 2015 and held it in 1 quarter.
UBS AM's Larimar Therapeutics position peaked at $1.22M in Q1 2015.
89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2015.

Based on UBS AM's 13F filing for Q2 2015, filed 12 Aug 2015.